Medicine and Dentistry
Positron Emission Tomography
100%
Neoplasm
91%
Positron Emission Tomography-Computed Tomography
67%
Polyethylene Terephthalate
65%
Cervical Cancer
50%
Radiation Therapy
49%
Fluorodeoxyglucose F 18
39%
Diseases
36%
Pelvis
28%
Fluorine-18
27%
Carcinoma
26%
Fluorodeoxyglucose
25%
Neuroendocrine Tumor
23%
Computer Assisted Tomography
23%
Brachytherapy
21%
Recurrent Disease
20%
Gallium 68
20%
Magnetic Resonance Imaging
19%
Prostate Cancer
19%
Scintigraphy
19%
Metastatic Carcinoma
18%
Malignant Neoplasm
17%
Overall Survival
17%
Heart Muscle Blood Flow
16%
Cancer
16%
Radioactive Tracer
14%
Diagnosis
14%
Oncology
14%
Lymph Node
14%
Nuclear Medicine
13%
Cervix
13%
Coronary Artery Disease
13%
Standardized Uptake Value
12%
Uterine Cervix
12%
Lutetium 177
11%
Technetium-99
11%
Prostate Specific Membrane Antigen
11%
Treatment Planning
11%
Uterine Cervix Carcinoma
10%
Non Small Cell Lung Cancer
10%
Breast Cancer
10%
Uterine Cancer
9%
Radioisotope
9%
Biological Marker
9%
Clinical Trial
9%
Biopsy Technique
9%
Chemoradiotherapy
9%
Lymph Node Metastasis
9%
Intensity Modulated Radiation Therapy
9%
Molecular Imaging
9%
Progression Free Survival
8%
Distant Metastasis
8%
Prognostic Factor
8%
Radionuclide Therapy
8%
Single-Photon Emission Computed Tomography
8%
Somatostatin Receptor
8%
Primary Tumor
8%
Peptide Receptor
7%
Radiology
7%
Lung
7%
Radiopharmaceutical
7%
Pediatrics
7%
Heart Muscle Perfusion
7%
Low Drug Dose
7%
Coronary Circulation
7%
Dosimetry
7%
Pulmonary Embolism
7%
Drug Megadose
6%
Paraaortic Lymph Node
6%
Positron Emission Tomography - Magnetic Resonance Imaging
6%
Surgery
6%
Disease Free Survival
6%
Receptor
6%
Treatment Response
6%
Tetraxetan
6%
Cardiovascular System
6%
Bladder
6%
Myocardium
5%
External Beam Radiotherapy
5%
Castration Resistant Prostate Cancer
5%
Squamous Cell Carcinoma
5%
Metabolism
5%
Indium 111
5%
Lung Cancer
5%
Colorectal Carcinoma
5%
Implant
5%
Health Care Cost
5%
Myocardial Perfusion Imaging
5%
Platelet
5%
Bone Metastasis
5%
Liver Metastasis
5%
Radioligand
5%
Bone Scintigraphy
5%
Keyphrases
Positron Emission Tomography
71%
Positron Emission Tomography-computed Tomography (PET-CT)
59%
Tumor
50%
Cervical Cancer
48%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
30%
Cervical Carcinoma
29%
Irradiation
26%
Radiation Therapy
20%
Computed Tomography
19%
Neuroendocrine Tumor
18%
Overall Survival
17%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
17%
Fluorodeoxyglucose
17%
Myocardial Blood Flow
16%
Brachytherapy
16%
Radiotherapy
15%
SUVmax
15%
Prostate-specific Antigen
14%
Standardized Uptake Value
13%
Lutetium-177 (177Lu)
13%
Chemotherapy
12%
18F-fluorodeoxyglucose (18F-FDG)
12%
Distant Metastasis
11%
Magnetic Resonance Imaging
11%
Nuclear Medicine
11%
Single-photon Emission Computed Tomography (SPECT)
11%
18F-FDG PET-CT
10%
PET Imaging
10%
Prognostic Factors
10%
Radiopharmaceuticals
10%
Progression-free Survival
10%
PET-MRI
10%
Peptide Receptor Radionuclide Therapy
10%
Liver
9%
Technetium-99m
9%
Prostate Cancer
9%
Radiation Dose
8%
Scintigraphy
8%
Molecular Imaging
8%
Non-small Cell Lung Cancer (NSCLC)
8%
Coronary Artery Disease
8%
Pelvis
8%
Gallium-68
8%
Primary Tumor
7%
Perfusion
7%
Disease-free Survival
7%
Breast Cancer
7%
Radiation Therapy Oncology Group
7%
Intensity-modulated Radiation Therapy
7%
Dosimetry
7%
Intracavitary
7%
Confidence Interval
7%
Oncologic
7%
Stage IB
7%
Endometrial Cancer
6%
Tumor Response
6%
Radionuclides
6%
Tumor Volume
6%
High Dose
6%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
6%
Positron Emission tomography-CT
6%
Lymph Node Metastasis
6%
Invasive Cervical Cancer
6%
Left Ventricular Function
6%
Fluoro
6%
Patient Management
6%
Clinical Outcomes
6%
Myocardial Flow Reserve
6%
PET Image
6%
Clinical Trials
6%
Phase II Study
6%
Myocardial Perfusion
6%
Metastasis
6%
Metastatic Disease
6%
Concurrent Chemotherapy
6%
Whole-body
6%
Clinical Application
6%
Lung
6%
Recurrent Disease
5%
Metabolic Tumor Volume
5%
Pelvic Lymph Nodes
5%
Pulmonary Embolism
5%
FDG Uptake
5%
Para-aortic Lymph Node
5%
Oncology
5%
Imaging Studies
5%
Multivariate Analysis
5%
Locally Advanced Cervical Cancer
5%
National Oncologic PET Registry
5%
Cisplatin
5%
Cold Pressor
5%
Tumor Size
5%
HDR Brachytherapy
5%
Lung Cancer
5%
Treatment Planning
5%
Malignancy
5%
High Risk
5%
18F-fluoro-2-deoxy-D-glucose
5%
Cervical Cancer Patients
5%
Radiotracer
5%